公开(公告)号：EP1428825A1

公开(公告)日：2004-06-16

申请号：EP02767961.2

申请日：2002-09-18

申请人： Zeria Pharmaceutical Co., Ltd.

发明人： NAGASAWA, M.; c/o ZERIA PHARMACEUTICAL CO., LTD. ,  NISHIOKA, H.; c/o ZERIA PHARMACEUTICAL CO., LTD. ,  ASAMI, K.; c/o ZERIA PHARMACEUTICAL CO., LTD. ,  MIURA, N.; c/o ZERIA PHARMACEUTICAL CO., LTD. ,  SHINOZAKI, Y.; c/o ZERIA PHARMACEUTICAL CO., LTD ,  MORITA, H.; c/o ZERIA PHARMACEUTICAL CO., LTD

IPC分类号： C07D401/12 ,  A61K31/4439 ,  A61P1/04

CPC分类号： C07D401/12 ,  A61K31/4439

摘要： A benzimidazole derivative of formula (1):
(wherein R represents a hydrogen atom or a methoxy group, and n is 0 or 1) or a salt thereof; and a medicament containing the same.
The compounds of the present invention, due to minimized difference in therapeutic effect between subjects, which difference would otherwise be derived from different CYP2C19 activity from subject to subject, ensure that all patients can enjoy proper therapeutic effects at the same dose of the drug. Also, the compounds of the invention have low risk of drug interaction caused by induction of CYP1A family member enzymes, as well as low risk of development of cancer, and thus is useful as a remedy for peptic ulcer, reliably providing therapeutic effects with safety.

摘要翻译： 式（1）的苯并咪唑衍生物：其中R表示氢原子或甲氧基，n为0或1;或其盐; 和含有该药物的药物。 本发明的化合物由于受试者之间治疗效果的差异最小化，否则从受试者到受试者的不同CYP2C19活性的差异将确保所有患者在相同剂量的 毒品。 此外，本发明的化合物具有由诱导CYP1A家族成员酶引起的药物相互作用的低风险，以及癌症发展的低风险，因此可用作消化性溃疡的补救剂，可靠地提供安全的治疗效果。